Group items matching

in title, tags, annotations or url

Most survey-based prevalence estimates of type 1 diabetes among adults have been based on self-reported information about a young age at diagnosis (e.g.,30 years and 40 years) and insulin use within a year of diagnosis. However, this estimation approach misses type 1 diabetes in adults with older age of onset and may misclassify some cases of type 2 diabetes as type 1 if insulin use begins soon after diagnosis. The major goal of this project is to evaluate the validity of survey questions (or algorithms based on them) to distinguish between adults (aged 18 years of age) with type 1 and type 2 diabetes in a representative sample of adult diabetic patients in a diabetes patient registry or database. Using a gold standard, validity will be assessed by examining the sensitivity, specificity, and positive predictive value of algorithms to identify type of diabetes across demographic strata such as age, sex, and race. A secondary goal is to validate definitions of type of diabetes using electronic health records.

This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in Diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in Diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.Diabetescenters.org.

This announcement solicits applications for the Rural Health Care Coordination Network Partnership Program (Care Coordination Program). The purpose of the Rural Health Care Coordination Network Partnership Program is to support the development of formal, mature rural health networks that focus on care coordination activities for the following chronic conditions: diabetes, congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Care coordination in the primary care practice involves deliberately organizing patient care activities and sharing information among all of the participants concerned with a patient¿s care to achieve safer and more effective care. Rural Americans are unhealthier, with higher rates of chronic illnesses, such as diabetes, CHF, and COPD and have higher rates of high-risk behaviors such as smoking, physical inactivity, and poor nutrition.[1],[2],[3],[4] These high-risk behaviors cause many of the illnesses, suffering and deaths due to chronic diseases and conditions.[5] The increasing prevalence of chronic diseases and the high cost of health care in the U.S. bring treatment of the ¿whole¿ person to the forefront, especially as there are often psychosocial (psychological and social) issues related to chronic diseases; for example, there is a link between diabetes and depression. In addition, more mental health problems are seen in the primary care setting than other health care settings; thus, integrating behavioral health care into primary care helps address both the physical and psychosocial aspects of health and wellness. Reviews and reports from the Agency for Healthcare Quality and Research (AHRQ) have shown a positive impact from integrating a team approach to care for a variety of disease conditions.[6] Health care coordination for people living with chronic conditions is vital to providing high quality care, especially in rural areas where access to health care is an issue. The main goal of care coordi

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes that occurs during or after one or more episodes of acute pancreatitis. The teams will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have impaired glucose tolerance or diabetes mellitus after one or more episodes of acute pancreatitis due to various identifiable etiologies. Applications for the Data Coordinating Center (DCC) are submitted in response to a separate FOA: RFA-DK-19-023: Type 1 diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC) (U01).

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 Diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of Diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of Diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 Diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of Diabetes after acute pancreatitis.. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.

Grants of up to $1.62 million over five to seven years will be awarded to support investigators with an innovative basic, clinical, translational, epidemiological, or health services research initiative relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The program seeks to bring new perspectives to diabetes research by offering three types of funding: support for the transition from trainee to independent investigator, support for early-career diabetes investigators, and support for established investigators new to diabetes research.

The Sun Life Team Up Against Diabetes grant program is dedicated to addressing the prevention of Diabetes and its related complications. Grants are provided to nonprofit organizations throughout the country that focus on the following areas: Diabetes prevention, awareness, education, and care; Diabetes management; recovery and support from Diabetes-related complications; obesity prevention; and nutritional programs, including education, management, and awareness. Grants of $25,000, $50,000, or $100,000 are provided. The application deadline is March 31, 2018. Visit the Sun Life website to submit an online application.

This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) Diabetes (T3cDM) and in patients with newly diagnosed Diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the Diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-19-009 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).

This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) Diabetes (T3cDM) and in patients with newly diagnosed Diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the Diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-19-504 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.

his Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers, formerly named Diabetes Endocrinology Research Centers (DERCs) and Diabetes Research and Training Centers (DRTCs).Diabetes Research Centers are designed to support and enhance the national research effort in Diabetes, its complications, and related endocrine and metabolic diseases.

Research progress in the treatment for diseases of the exocrine pancreas [chronic pancreatitis (CP), pancreatogenic diabetes mellitus, and pancreatic cancer] has been hampered by the disorders' heterogeneity, the limitations of previous small cross-sectional studies, the inability to safely obtain pancreatic tissue for discovery, and the lack of structured epidemiology tools, genetic testing, and biomarker development and validation. Mechanism-based research of these diseases has suffered from the lack of systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. Given the increasing incidence and prevalence of CP and its association to the development of pancreatic cancer, its complications, high mortality rate, and associated health care cost, the National Institute for diabetes and Digestive and Kidney Diseases and the National Cancer Institute established in 2015 the Study of Chronic Pancreatitis, diabetes and Pancreatic Cancer (CPDPC) Consortium as multidisciplinary teams composed of members from the Clinical Centers and Coordination and Data Management Center to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with CP (including adults and children with recurrent acute pancreatitis) to develop treatments and gain insight into the pathophysiology of CP and its sequela: chronic pain, pancreatic exocrine and endocrine insufficiency, T3cDM, and the diabetes/pancreatic cancer association. Another objective was to undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients

This Funding Opportunity Announcement (FOA) invites applications for a Center for Identification and Study of Individuals with Atypical Diabetes Mellitus (U54). The purpose of this Center is to: foster the study of individuals with rare/atypical forms of Diabetes mellitus; identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of Type 2 Diabetes mellitus (T2DM) in the general population; and develop a community resource to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. To achieve this goal, the Center should support the following primary research endeavors: (1) develop a process for identifying and studying individuals/families with rare and uncharacterized forms of Diabetes and (2) create and manage a database and biospecimen repository of rare/atypical forms of Diabetes for use by the broader research community in future analyses.

The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to conduct surveillance to assess the incidence and prevalence of diabetes among children, adolescents and young adults in the United States and provide estimates by diabetes type, age, sex, race/ethnicity and geographic area. This NOFO has three (3) components to achieve the purpose of the program * Component A focuses on surveillance of incidence and prevalence of diabetes among children and adolescents (<45 years). * Component C serves as a Coordinating Center to provide an infrastructure for standardized approaches, analytical methods, and surveillance measures. It also serves as a repository for the Component A and B data and provides consolidated estimates by diabetes type, age, race/ethnicity and geographic area.

The American Diabetes Association's Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of Diabetes.  To that end, the organization is accepting applications for its Innovative Basic Science (IBS) and Innovative Clinical or Translational Science (ICTS) Research Awards. Through the IBS program, grants of up to $115,000 a year for up to three years will be awarded in support of basic research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of Diabetes. Through the ICTS program, grants of up to $200,000 a year for up to three years will be awarded in support of research performed in human subjects, or research approaches designed to accelerate the transition of scientific discoveries into clinical application. Studies supported by these awards must directly involve human samples and/or data and should offer considerable potential for advancing the cure, prevention, and/or treatment of Diabetes.

The purpose of this Funding Opportunity Announcement (FOA) is to continue the SEARCH for Diabetes in Youth Study. The overarching goal of SEARCH is to provide population-based data on the incidence and prevalence of Diabetes and its complications in U.S. youth. SEARCH has recruited a cohort of youth with Diabetes who have been followed longitudinally. The purpose of this FOA is to continue follow-up of the SEARCH cohort to understand the clinical course of youth-onset Diabetes, including the incidence of acute and chronic complications, including mortality, and processes of care and quality of life.

The purpose of this Funding Opportunity Announcement (FOA) is to continue the SEARCH for Diabetes in Youth Study. The overarching goal of SEARCH is to provide population-based data on the incidence and prevalence of Diabetes and its complications in U.S. youth. SEARCH has recruited a cohort of youth with Diabetes who have been followed longitudinally. The purpose of this FOA is to continue follow-up of the SEARCH cohort to understand the clinical course of youth-onset Diabetes, including the incidence of acute and chronic complications, including mortality, and processes of care and quality of life.  - See more at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-508.html#sthash.WZygd0KM.dpuf

he purpose of this Center is to: foster the study of individuals with rare/atypical forms of diabetes mellitus; identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of Type 2 diabetes mellitus (T2DM) in the general population; and develop a community resource to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. To achieve this goal, the Center should support the following primary research endeavors: (1) develop a process for identifying and studying individuals/families with rare and uncharacterized forms of diabetes and (2) create and manage a database and biospecimen repository of rare/atypical forms of diabetes for use by the broader research community in future analyses.

Pathway supports innovative basic, clinical, translational, epidemiological, behavioral, or health services research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The Association seeks exceptional candidates from a broad range of disciplines, including medicine, biology, chemistry, computing, physics, mathematics and engineering.

NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for Diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known Diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing.

This NOFO has two components, A and B. Component A (Natural Experiment Research Centers): To support a 5-year multi-center network of independent research centers to evaluate innovative, health system and non-health system-based natural experimental approaches to alter the diabetogenic characteristics of US communities. Applicants will select one of the following two tracks: Track 1 Evaluation of population-level programs or policies that affect population-level risk factors for type 2 diabetes (such as diet or physical activity, as well as other health behaviors; glucose; prediabetes), or Track 2 Evaluation of programs or policies aimed at improving care and management of diabetes, and the risk for diabetes complications. Component B (Coordinating Center): To fund a Coordinating Center (CC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and public health impact of the Natural Experiments research centers that are funded as part of Component A.